211 related articles for article (PubMed ID: 17475912)
1. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.
Caligiuri MA; Briesewitz R; Yu J; Wang L; Wei M; Arnoczky KJ; Marburger TB; Wen J; Perrotti D; Bloomfield CD; Whitman SP
Blood; 2007 Aug; 110(3):1022-4. PubMed ID: 17475912
[TBL] [Abstract][Full Text] [Related]
2. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
Reindl C; Quentmeier H; Petropoulos K; Greif PA; Benthaus T; Argiropoulos B; Mellert G; Vempati S; Duyster J; Buske C; Bohlander SK; Humphries KR; Hiddemann W; Spiekermann K
Clin Cancer Res; 2009 Apr; 15(7):2238-47. PubMed ID: 19276253
[TBL] [Abstract][Full Text] [Related]
3. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.
Fernandes MS; Reddy MM; Croteau NJ; Walz C; Weisbach H; Podar K; Band H; Carroll M; Reiter A; Larson RA; Salgia R; Griffin JD; Sattler M
J Biol Chem; 2010 Oct; 285(42):32596-605. PubMed ID: 20622007
[TBL] [Abstract][Full Text] [Related]
4. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
[TBL] [Abstract][Full Text] [Related]
5. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.
Goyama S; Schibler J; Gasilina A; Shrestha M; Lin S; Link KA; Chen J; Whitman SP; Bloomfield CD; Nicolet D; Assi SA; Ptasinska A; Heidenreich O; Bonifer C; Kitamura T; Nassar NN; Mulloy JC
Leukemia; 2016 Mar; 30(3):728-39. PubMed ID: 26449661
[TBL] [Abstract][Full Text] [Related]
6. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
Makishima H; Cazzolli H; Szpurka H; Dunbar A; Tiu R; Huh J; Muramatsu H; O'Keefe C; Hsi E; Paquette RL; Kojima S; List AF; Sekeres MA; McDevitt MA; Maciejewski JP
J Clin Oncol; 2009 Dec; 27(36):6109-16. PubMed ID: 19901108
[TBL] [Abstract][Full Text] [Related]
7. The protein content of an adaptor protein, STAP-2 is controlled by E3 ubiquitin ligase Cbl.
Sekine Y; Yamamoto C; Ikeda O; Muromoto R; Nanbo A; Oritani K; Yoshimura A; Matsuda T
Biochem Biophys Res Commun; 2009 Jun; 384(2):187-92. PubMed ID: 19401194
[TBL] [Abstract][Full Text] [Related]
8. Flt3-dependent transformation by inactivating c-Cbl mutations in AML.
Sargin B; Choudhary C; Crosetto N; Schmidt MHH; Grundler R; Rensinghoff M; Thiessen C; Tickenbrock L; Schwäble J; Brandts C; August B; Koschmieder S; Bandi SR; Duyster J; Berdel WE; Müller-Tidow C; Dikic I; Serve H
Blood; 2007 Aug; 110(3):1004-12. PubMed ID: 17446348
[TBL] [Abstract][Full Text] [Related]
9. Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias.
Abbas S; Rotmans G; Löwenberg B; Valk PJ
Haematologica; 2008 Oct; 93(10):1595-7. PubMed ID: 18698078
[No Abstract] [Full Text] [Related]
10. CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors.
Makishima H; Sugimoto Y; Szpurka H; Clemente MJ; Ng KP; Muramatsu H; O'Keefe C; Saunthararajah Y; Maciejewski JP
Leukemia; 2012 Jul; 26(7):1547-54. PubMed ID: 22246246
[TBL] [Abstract][Full Text] [Related]
11. Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.
Bacher U; Haferlach C; Schnittger S; Kohlmann A; Kern W; Haferlach T
Ann Hematol; 2010 Jul; 89(7):643-52. PubMed ID: 20195608
[TBL] [Abstract][Full Text] [Related]
12. CBL mutations do not frequently occur in paediatric acute myeloid leukaemia.
Coenen EA; Driessen EM; Zwaan CM; Stary J; Baruchel A; de Haas V; de Bont ES; Reinhardt D; Kaspers GJ; Arentsen-Peters ST; Meyer C; Marschalek R; Pieters R; Stam RW; van den Heuvel-Eibrink MM
Br J Haematol; 2012 Dec; 159(5):577-84. PubMed ID: 23025505
[TBL] [Abstract][Full Text] [Related]
13. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
Hartman AD; Wilson-Weekes A; Suvannasankha A; Burgess GS; Phillips CA; Hincher KJ; Cripe LD; Boswell HS
Exp Hematol; 2006 Oct; 34(10):1360-76. PubMed ID: 16982329
[TBL] [Abstract][Full Text] [Related]
14. The adaptor molecule CIN85 regulates Syk tyrosine kinase level by activating the ubiquitin-proteasome degradation pathway.
Peruzzi G; Molfetta R; Gasparrini F; Vian L; Morrone S; Piccoli M; Frati L; Santoni A; Paolini R
J Immunol; 2007 Aug; 179(4):2089-96. PubMed ID: 17675467
[TBL] [Abstract][Full Text] [Related]
15. Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms.
Ogawa S; Shih LY; Suzuki T; Otsu M; Nakauchi H; Koeffler HP; Sanada M
Clin Cancer Res; 2010 Aug; 16(15):3825-31. PubMed ID: 20547695
[TBL] [Abstract][Full Text] [Related]
16. c-Cbl tyrosine kinase-binding domain mutant G306E abolishes the interaction of c-Cbl with CD38 and fails to promote retinoic acid-induced cell differentiation and G0 arrest.
Shen M; Yen A
J Biol Chem; 2009 Sep; 284(38):25664-77. PubMed ID: 19635790
[TBL] [Abstract][Full Text] [Related]
17. c-Cbl tyrosine phosphorylation and subcellular localization in human primary leukemic cells.
Brizzi MF; Rosso A; Dentelli P; Ferrero D; Lanfrancone L; Pegoraro L
Exp Hematol; 1998 Dec; 26(13):1229-39. PubMed ID: 9845379
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitin ligase Cbl-b and inhibitory Cblin peptides.
Nikawa T; Ishidoh K
Biochim Biophys Acta Proteins Proteom; 2020 Nov; 1868(11):140495. PubMed ID: 32663526
[TBL] [Abstract][Full Text] [Related]
19. Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases.
Polzer H; Janke H; Schmid D; Hiddemann W; Spiekermann K
Exp Hematol; 2013 Mar; 41(3):271-80.e4. PubMed ID: 23127761
[TBL] [Abstract][Full Text] [Related]
20. H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b.
Vennin C; Spruyt N; Dahmani F; Julien S; Bertucci F; Finetti P; Chassat T; Bourette RP; Le Bourhis X; Adriaenssens E
Oncotarget; 2015 Oct; 6(30):29209-23. PubMed ID: 26353930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
